Tseng Chin-Hsiao
Department of Internal Medicine, National Taiwan University College of Medicine, No. 7 Chung-Shan South Road, Taipei, (100), Taiwan.
Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
BMC Cancer. 2015 Feb 6;15:41. doi: 10.1186/s12885-015-1057-8.
Whether rosiglitazone may affect the risk of non-melanoma skin cancer (NMSC) has not been investigated.
The reimbursement databases of all Taiwanese diabetic patients from 1996 to 2009 were retrieved from the National Health Insurance. An entry date was set at 1 January 2006 and a total of 886418 patients with type 2 diabetes were followed up for NMSC incidence until the end of 2009. Incidences for ever-users, never-users and subgroups of rosiglitazone exposure (using tertile cutoffs of duration of therapy and cumulative dose) were calculated and hazard ratios estimated by Cox regression. Additional models were created as sensitivity analyses.
There were 103097 ever-users and 783321 never-users, respective numbers of incident NMSC 250 (0.24%) and 2084 (0.27%), and respective incidence 68.90 and 76.77 per 100000 person-years. Although the overall hazard ratio was not significant in the unadjusted, age-sex-adjusted or fully adjusted model, the risk was significantly lower in the third tertile of duration of therapy and cumulative dose, with significant P for trends. The fully adjusted hazard ratio (95% confidence interval) for a duration of therapy >13.77 months and a cumulative dose of >1752 mg was 0.723 (0.566, 0.923) and 0.783 (0.618, 0.993), respectively. The findings were supported by various sensitivity analyses.
Rosiglitazone may reduce the risk of NMSC, but further confirmation is required.
罗格列酮是否会影响非黑色素瘤皮肤癌（NMSC）的风险尚未得到研究。
从国民健康保险中检索了1996年至2009年所有台湾糖尿病患者的报销数据库。设定入组日期为2006年1月1日，对总共886418例2型糖尿病患者进行随访，直至2009年底，观察NMSC发病率。计算曾经使用者、从未使用者以及罗格列酮暴露亚组（根据治疗持续时间和累积剂量的三分位数划分）的发病率，并通过Cox回归估计风险比。创建了其他模型作为敏感性分析。
曾经使用者有103097例，从未使用者有783321例，NMSC的发病例数分别为250例（0.24%）和2084例（0.27%），发病率分别为每100000人年68.90例和76.77例。尽管在未调整模型、年龄性别调整模型或完全调整模型中，总体风险比均无统计学意义，但在治疗持续时间和累积剂量的第三个三分位数中，风险显著降低，趋势P值具有统计学意义。治疗持续时间>13.77个月且累积剂量>1752 mg时，完全调整后的风险比（95%置信区间）分别为0.723（0.566，0.923）和0.783（0.618，0.993）。各种敏感性分析支持了这些发现。
罗格列酮可能会降低NMSC的风险，但需要进一步证实。
